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Abstract
We recently reported that peritumoral CpG-ODN treatment, activating TLR-9 expressing cells in tumor microenvironment,
induces modulation of genes involved in DNA repair and sensitizes cancer cells to DNA-damaging cisplatin treatment. Here,
we investigated whether this treatment induces modulation of miRNAs in tumor cells and their relevance to chemotherapy
response. Array analysis identified 20 differentially expressed miRNAs in human IGROV-1 ovarian tumor cells from CpG-ODN-
treated mice versus controls (16 down- and 4 up-regulated). Evaluation of the role of the 3 most differentially expressed
miRNAs on sensitivity to cisplatin of IGROV-1 cells revealed significantly increased cisplatin cytotoxicity upon ectopic
expression of hsa-miR-302b (up-modulated in our array), but no increased effect upon reduced expression of hsa-miR-424
or hsa-miR-340 (down-modulated in our array). Accordingly, hsa-miR-302b expression was significantly associated with time
to relapse or overall survival in two data sets of platinum-treated ovarian cancer patients. Use of bio-informatics tools
identified 19 mRNAs potentially targeted by hsa-miR-302b, including HDAC4 gene, which has been reported to mediate
cisplatin sensitivity in ovarian cancer. Both HDAC4 mRNA and protein levels were significantly reduced in IGROV-1 cells
overexpressing hsa-miR-302b. Altogether, these findings indicate that hsa-miR-302b acts as a ‘‘chemosensitizer’’ in human
ovarian carcinoma cells and may represent a biomarker able to predict response to cisplatin treatment. Moreover, the
identification of miRNAs that improve sensitivity to chemotherapy provides the experimental underpinning for their
possible future clinical use.
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Introduction
Oligodeoxynucleotides (ODN) containing dinucleotides with
unmethylated CpG motifs (CpG-ODN) are potent activators of
both the innate and adaptive immune systems [1;2]. Recognition
of CpG-ODN is mediated by Toll-like receptor 9 (TLR9), an
endosomal member of the TLR family, which is critically
important in detecting microbial pathogens. In a xenograft model
of human IGROV-1 ovarian cancer, we recently showed that
treatment with CpG-ODN induced down-modulation of DNA
repair genes in tumor cells and that peritumoral injection of CpG-
ODN in the peritoneal cavity was for inducing this down-
modulation [3] and for the antitumor activity of CpG-ODN [4].
Considering the CpG-ODN species specificity and to the lack of
TLR9 expression on IGROV1 cells, the effect cannot be mediated
by a direct interaction between the oligonucleotide and tumor
cells, instead it is likely that peritumoral TLR9-expressing cells,
such as innate immune cells and/or endothelial cells, fibroblasts
and epithelial cells, directly respond to CpG-ODN and down-
regulate DNA repair in tumor cells through a direct cell-cell
interaction and/or by secreting soluble factors.
MicroRNAs (miRNAs) are short (,22 nucleotide), non-coding
RNAs known to alter gene expression at the post-transcriptional
level [5;6]. More than 1,200 human miRNAs have been identified
and validated to date (www.mirbase.org), and are predicted to
regulate about one-third of the human genome, with involvement
in development and progression of many diseases [7–9].
Presumably, miRNAs evolved to allow organisms and cells to
effectively deal with stress [10]. Recent studies demonstrating that
a single miRNA can impact hundreds of targets [11] and that
multiple miRNAs can affect a single target [12] point to broad
implications of miRNAs, able to affect all most important cellular
processes. Indeed, several experimental and clinical findings have
also implicated miRNAs in the response to chemotherapy [13],
demonstrating a role for miRNAs in the modulation of genes
involved in DNA repair [14;15].
The CpG-ODN-induced down-modulation of DNA repair
genes in tumor cells might represent a physiologic phenomenon
that occurs locally in the presence of an infectious event. Upon
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detection of an infectious agent via endosomal TLRs, cells
involved in the immune response might induce modulation of
DNA repair genes in infected (or transformed) cells to facilitate
their death [16]. Identification of miRNAs that are used
‘‘physiologically’’ to modulate DNA repair genes may have
therapeutic implications.
In the present study, we analyzed the effect of CpG-ODN on
modulation of miRNAs in tumor cells, the integration of miRNA
with mRNA expression modulation induced by CpG-ODN, and
the relevance of the identified miRNAs for the response to
chemotherapy.
Materials and Methods
Ethical Commitee
The in vivo experiment was approved by the Ethics Committee
for Animal Experimentation of the Fondazione IRCCS Istituto
Nazionale Tumori of Milan according to institutional guidelines.
Drugs and Antibodies
Purified phosphorothioated ODN1826 (59-TCCAT-
GACGTTCCTGACGTT-39) containing CpG motifs was syn-
thesized by TriLink Biotechnologies (San Diego, CA, USA).
Phosphorothioate modification was used to reduce susceptibility of
the ODN to DNase digestion, thereby significantly prolonging its
in vivo half-life. Cisplatin was purchased from Teva Italia (Milan,
Italy). Anti-HDAC4 (D15C3), anti-p21 (sc-397) and anti-GAPDH
(GAPDH-71.1) antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA), Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and Sigma (St. Louis, MO, USA),
respectively.
Cells
Human IGROV-1 ovarian tumor cells (gift from Dr. J. Benard,
Institute Gustave Roussy, Villejuif, France) were adapted to
growth i.p. and maintained by serial i.p. passage of ascitic cells into
healthy mice as described [3,17]. Every 6 months, cells were
authenticated by morphologic inspection and by FACS analysis
for the presence of specific markers. For in vitro experiments,
IGROV-1 cells were maintained in RPMI medium 1640
supplemented with 10% FCS (Sigma) and 2 mM glutamine
(Cambrex, East Rutherford, NJ, USA) at 37uC in a 5% CO2 air
atmosphere.
miRNA Extraction from Tumor Samples
miRNAs were extracted from the IGROV-1 xenograft tumors
used for gene expression analysis or from a replica of the in vivo
experiment [3]. Briefly, solid i.p. masses were mechanically
disrupted and homogenized in the presence of QIAzol Lysis
reagent (Qiagen, Valencia, CA, USA) using a Mikrodismembrator
(Braun Biotech International, Melsungen, Germany). RNA was
extracted using the miRNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions. RNA concentrations were measured
with the NanoDrop ND-100 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA), while RNA quality was
assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA USA) using the RNA 6000 Nano kit (Agilent).
Samples included in the present analysis had a RIN (RNA
Integrity Number) score .7 and a 28S:18S rRNA ratio ,2:1.
miRNA Expression Profiling
Mature miRNAs were detected with the Illumina Human_v2
MicroRNA expression profiling kit, based on the DASL (cDNA-
mediated Annealing, Selection, Extension, and Ligation) assay,
according to the manufacturer’s instructions (Illumina Inc., San
Diego, CA, USA). Briefly, 600 ng/sample total RNA was
converted to cDNA followed by annealing of a miRNA-specific
oligonucleotide pool consisting of: i) a universal PCR priming site
at the 59 end; ii) an address sequence complementary to a capture
sequence on the BeadArray; and iii) a miRNA-specific sequence at
the 39 end. After PCR amplification and fluorescent labeling,
probes were hybridized on Illumina miRNA BeadChips, washed,
and fluorescent signals were detected by the Illumina BeadAr-
rayTM Reader. Data were collected using BeadStudio V3.0
Figure 1. miRNA expression profiling in IGROV-1 ovarian
tumors from CpG-ODN-treated athymic mice. Heat-map of 23
modulated miRNAs with FDR ,0.1 and fold change .1.8 in CpG-ODN-
versus saline-treated mice. Among the 20 miRNAs belonging to
miRBase12.0, 16 were down- and 4 up-modulated in CpG-ODN-treated
mice (red: up-regulated miRNAs; green: down-modulated miRNAs).
Columns and rows represent samples and miRNAs, respectively.
doi:10.1371/journal.pone.0058849.g001
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software. Raw and normalized data are available on the Gene
Expression Omnibus website with accession numbers GSE41783
and GSE23441 for miRNA and gene expression profiling,
respectively.
Real-time Quantitative PCR (RT-qPCR)
RT-qPCR microRNA assays specific for hsa-miR-18a, hsa-
miR-18b, hsa-miR-140-5p, hsa-miR-101, hsa-miR-556-3p, hsa-
miR-424, hsa-miR-136, hsa-miR-340, hsa-miR-302b were pur-
chased from Exiqon (Vedbaek, Denmark). RT-qPCR was
performed using the miRCURY LNA Universal RT microRNA
PCR system (Exiqon) according to the manufacturer’s instructions.
Total RNA (20 ng) was polyadenylated and reverse-transcribed at
42uC (60 min), followed by heat-inactivation at 85uC (5 min) using
a poly-T primer containing a 59 universal tag. The resulting cDNA
was diluted 80-fold and 8 ml used in 20-ml PCR amplification
reactions at 95uC for 10 min, 40 cycles of 95uC for 10 sec, and
60uC for 60 sec. Results were normalized with snord48 (Assay
ID:203903). P-values were calculated using two-tailed Student’s t-
test.
Figure 2. Independent biological validation of CpG-ODNmiRNA profile.miRNA expression was assessed by RT-qPCR on IGROV-1 xenografts
collected from a replica of a previous experiment [3]. RT-qPCR data are plotted as 2DCt. P-values were calculated using two-tailed Student’s t-test.
doi:10.1371/journal.pone.0058849.g002
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Bioinformatics Analysis
Analyses were performed using BRB-Array Tools v4.0 stable
release developed by Dr. Richard Simon (NCI) and the BRB-
Array Tools development team (EMMES Corp.) and the R
package (http://www.bioconductor.org/). The same data-process-
ing was used in both miRNA and gene expression profiling to
improve data integration. Quantile normalization was used to
correct experimental distortions. A detection threshold of p,0.05
was set for each gene and miRNA. Probes detected in less than
50% of the samples were eliminated from the analysis. Genes and
miRNAs differentially expressed were identified using a random-
variance t-test, which allows computation of a t-test statistic for
each detected miRNA and genes between the classes of samples
under investigation without assuming that all miRNAs have the
same variance [18]. To limit the number of false-positive findings,
miRNAs and genes were considered statistically significant at a
false-discovery rate (FDR) ,0.1. To identify the most likely
targets, mRNA and miRNA expression data were integrated using
the MAGIA web tool [19]. A parametric linear correlation
measure (Pearson’s correlation coefficient, recommended for
normally distributed data and a sample size .5) was used to
assess the degree of anti-correlation between miRNA and gene
expression data.
In silico Bioinformatics Analyses
Two publicly available datasets GSE27290 [20] and GSE25204
[21] reporting miRNA expression and clinical annotated data
were downloaded from the Gene Expression Omnibus (GEO)
database. The former dataset consists of 62 diagnosed patients
with stage III or IV serous ovarian cancer profiled on a pre-
commercial version of miRNA chips (GPL7341) designed on
miRBase 9.1. Raw array data were processed using GeneSpring
software (Agilent) and quantile-normalized. The latter dataset
reports profiling of 85 stage III or IV epithelial ovarian cancers,
divided into a training set (55 cases) and test set (30 cases), profiled
with Illumina human_v2 MicroRNA chips. Raw data were
processed and quantile-normalized using BeadStudio V3.0 soft-
ware. Non-biological experimental variations between training
and test sets were adjusted using ComBat [22].
Statistical Analysis
The clinical impact on overall survival (OS) and time to relapse
(TTR) in GSE27290 and GSE25204, respectively, was assessed by
the Kaplan-Meier method, and differences between curves were
compared using a non-parametric (log-rank) test, with hazard
ratios and 95% confidence intervals also computed. GraphPadPr-
ism v5 (GraphPad software, La Jolla, CA, USA) was used for
statistical analyses.
miRNA Transfection and Cell Viability Analysis
IGROV-1 cells seeded in 6-well plates at 26105 cells/well were
transfected with miRCURY LNA inhibitors of hsa-miR-424 or
hsa-miR-340 or negative control A (Exiqon; final concentration,
100 nmol/L) using SiPort Neo-FX (Ambion) according to the
manufacturer’s instructions, or with hsa-miR-302b precursor or
negative control #1 pre-miR (Ambion; final concentration,
50 nmol/l). Transfections were verified by qRT-PCR as described
above. Cell viability after cisplatin treatment were assessed by
propidium iodide staining and flow cytometry as described [3].
Cell Growth Assay
IGROV-1 cells were transfected with 50 nmol/l pre-hsa-miR-
302b or scrambled oligonucleotide using SiPort Neo-FX transfec-
tion reagent according to the manufacturer’s protocol (Ambion)
and seeded in a 96-well plate at a density of 103, 1.56103, and
26103 cells/well. After 72 h of culture, cells were fixed with 10%
trichloroacetic acid for 1 h at 4uC, washed 5 times with distilled
and de-ionized water, air-dried, and incubated with 100 ml
sulforodamine (SRB) 0.4% (w/v) for 30 min. Cells were then
washed 4 times with 1% acetic acid, air-dried, and 10 mM Tris
solution (pH 10.5) added to dissolve the bound dye. Cell growth
was assessed based on optical density (OD) at 550 nm using an
ELISA microplate reader (Bio-Rad Lab, Inc., Hercules, CA,
USA).
Immunoblotting
Transfected cells were lysed in lysis buffer containing 50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100 (Sigma),
10% (vol/vol) glycerol, 2 mM Na-orthovanadate, 10 mM leupep-
tin, 10 mM aprotinin, 1 mM phenylmethylsulfonyl-fluoride,
100 mM Na-fluoride, and 10 mM Na-pyrophosphate for 30 min
Figure 3. Forced expression of hsa-miR-302b increased cisplat-
in sensitivity in IGROV-1 cells without affecting cell prolifera-
tion. (A) Percent cell death of hsa-miR-302b- and scrambled-
transfected cells after cisplatin treatment. IGROV-1 cells were transfect-
ed with 50 nmol/l hsa-miR-302b precursor molecule or scrambled
control, and 72 h later, exposed to cisplatin (50 mM) for 1 h. Cell viability
was assessed 24 h after cisplatin treatment by propidium iodide
staining and flow cytometry. Data represent mean 6 SEM of 6
independent experiments. ***p,0.0001 by paired t-test. (B) Evaluation
of cell proliferation by SRB assay. Transfected cells were seeded in a 96-
well plate at a density of 103, 1.56103, and 26103 cells/well. Cell growth
was assessed by optical density (OD) determination 72 h after
transfection. Data represent mean 6 SEM of 3 independent experi-
ments.
doi:10.1371/journal.pone.0058849.g003
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at 4uC. Insoluble material was removed by 10-min centrifugation
at 15,500 6 g at 4uC. Protein concentrations were determined
using the Coomassie technique. Equal amounts of total lysates
(20 mg) were loaded and separated on 10% precast NuPage SDS-
Bis-Tris gels (Invitrogen) and transferred to PVDF membranes
(Millipore, Billerica, MA, USA). Western blots were performed
with the indicated antibodies, and binding was detected with
peroxidase-conjugated secondary antibodies and chemilumines-
cence ECL (GE Healthcare, Little Chalfont, UK) according to the
manufacturer’s instructions. Quantitation of p21 protein levels
reportedly regulated post-transcriptionally by miRNAs of the hsa-
miR-302 family [23] revealed the expected down-regulation of this
protein in IGROV-1 cells transfected with hsa-miR-302b precur-
sor (data not shown), suggesting that hsa-miR-302b exerts
biological effects in IGROV-1 cells similar to those observed in
other cellular models.
Plasmid Construction
For luciferase reporter experiments, a 1017-bp region of the
HDAC4 39 untranslated region including the binding site for hsa-
miR-302b was amplified from IGROV-1 cells. The PCR product
was digested with XbaI and cloned into the reporter plasmid
pGL3 control (Promega, Madison, WI, USA) downstream of the
luciferase gene. Mutations into the hsa-miR-302b binding site of
the HDAC4-39UTR were introduced using Quik-Change II Site-
Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA).
Figure 4. Computational integration of miRNA and gene expression profiles of tumor samples from CpG-ODN- and saline-treated
mice. Network between 15 of 20 differentially expressed miRNAs and their anti-correlated target genes. The top 250 interactions were used to
generate the network using the MAGIA tool.
doi:10.1371/journal.pone.0058849.g004
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HDAC4-wt-Fw: 59-AATTTCTAGAGGGGGACTTAATTC-
TAATCTCATT-39.
HDAC4-wt-Rw: 59-AATTTCTAGATTTTGTGTCAGAC-
CATTACGAA-39.
HDAC4-Mut-Fw: 59-GCACTGGCTGGGAGTCAG-
CAAGCGCCGCGGGTATATCCCTTTGACG-
GAAACCCTG-39.
HDAC4-Mut-Rw: 59-CAGGGTTTCCCTCAAAGGGATA-
TACCCGCGGCGCTTGCTGACTCCCAGCCAGTGC-39.
Luciferase Assays for Target and Promoter Identification
pGL3 reporter vector (200 ng) containing the hsa-miR-302b
binding site, 40 ng of the phRL-SV40 control vector (Promega),
and 50 nmol/l miRNA precursors or scrambled sequence miRNA
control (Ambion Inc, Austin, TX. USA) were co-transfected into
IGROV-1 cells in 48-well plates. Cells were transfected with
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Firefly luciferase activity was measured with a Dual
Luciferase Assay Kit (Promega) 48 h after transfection and
normalized with a Renilla luciferase reference plasmid. Reporter
Figure 5. Targeting of HDAC4 in IGROV-1 cells by hsa-miR-302b. IGROV-1 cells were transfected with 50 nmol/l hsa-miR-302b or a scrambled
oligonucleotide and RNA and proteins were collected after 72 h. HDAC4 mRNA levels were evaluated by RT-qPCR (A) and protein expression was
evaluated by Western blot (B). GAPDH was used to normalize protein loading per lane. Data are representative of 6 independent experiments with
superimposable results. (C) Schematic representation of the interaction between hsa-miR-302b and the binding site on the wild-type HDAC4-39UTR
and the mutated control. (D) Relative luciferase activity in IGROV-1 cells for HDAC4-39UTR-wt co-transfected with reporter vector and with hsa-miR-
302b precursor molecule or negative scrambled control for 48 h. (E) Relative luciferase activity in IGROV-1 cells for HDAC4-39UTR-mut co-transfected
with reporter vector and with hsa-miR-302b precursor molecule or negative scrambled control for 48 h.
doi:10.1371/journal.pone.0058849.g005
Cisplatin Sensitivity Modulated by miRNA
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assays were carried out in quadruplicate. Data (mean6S.E.M.)
were analyzed using unpaired Student’s t-test.
Results
Differentially Expressed miRNAs in IGROV-1 Ovarian
Tumors from CpG-ODN-Treated Mice
RNA extracted from omentum-adherent tumors of human
IGROV-1 ovarian carcinoma-bearing mice treated i.p. with CpG-
ODN or saline (control group) as described [3] was analyzed for
miRNA expression using Illumina human miRNA_v2 array. Out
of 1145 miRNAs represented on the Illumina chips, 567 mature
miRNAs annotated on miRBase12.0, along with 150 putative
miRNAs, were consistently detected. Class comparison identified
23 miRNAs showing a FDR,0.1 and a fold-change.1.8 between
CpG-ODN- and saline-treated mice (Fig. 1). Among them, 20
miRNAs (16 up-regulated in saline- and 4 in CpG-ODN-treated
mice) were annotated on miRBase12.0, whereas 3 miRNAs were
putative miRNA sequences derived from deep- sequencing
approaches as referred by Berezikov et al. [24] and Solexa
(Illumina), which were excluded from further analysis due to the
lack of information.
To validate the microarray data, 9 differentially expressed
miRNAs were analyzed by RT-qPCR using both the RNA
profiled in microarray analysis and the RNA extracted from tumor
samples obtained from a replica of the IGROV-1 tumor-bearing
mice treated as described [3]. Of the 9 miRNAs, hsa-miR-18a and
hsa-miR-18b were selected based on their reported role in the
pathogenesis of ovarian cancer [25;26], and hsa-miR-101 and hsa-
miR-302b for their described involvement in DNA repair
processes and sensitivity to chemotherapy [20]; the remaining 5
miRNAs were randomly selected. RT-qPCR using the RNA
profiled in microarray analysis validated all 9 miRNAs (Fig. S1),
whereas RT-qPCR using the RNA of the replica confirmed 6 of 9
miRNAs (p,0.05), with a trend observed for hsa-miR-18b and
hsa-miR-101 but not for hsa-miR-136 (Fig. 2).
Increased Expression of hsa-miR-302b in IGROV-1 Cells
Significantly Improved Cisplatin Activity
We previously showed that TLR9-expressing cells in the tumor
microenvironment can sensitize cancer cells to DNA-damaging
cisplatin treatment by down-modulating genes involved in DNA
repair [3]. To determine whether miRNAs modulated by CpG-
ODN treatment are able to modify the sensitivity to DNA-
Figure 6. In silico evaluation of ovarian cancer patients’ clinical course according to hsa-miR-302b and hsa-miR-340 expression
levels. Kaplan-Meier survival curves of patients stratified according to hsa-miR-302b expression (A) and has-miR-340 expression (B) on GSE25204 and
referred to TTR. (C) Kaplan-Meier survival curves for hsa-miR-302b expression on GSE27290 and referred to OS. Patients were dichotomized using
median expression as threshold.
doi:10.1371/journal.pone.0058849.g006
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damaging agents, the 3 most significantly differentially expressed
miRNAs in tumor samples obtained from the replica of the in vivo
experiment (hsa-miR-424, hsa-miR-340 and hsa-miR-302b) were
examined applying a gain- or loss-of-function phenotype in order
to mimic the up- or down-modulation observed in miRNA
profiling (see Fig. 1). To reduce expression of hsa-miR-424 and
hsa-miR-340 (down-modulated in our miRNA expression profile),
IGROV-1 cells were transiently transfected for 72 h with the
respective LNA inhibitors or with a LNA negative control,
whereas cells were transfected with hsa-miR-302b precursor
molecule (or a scrambledoligonucleotide) to increase expression
of hsa-miR-302b. Cells were then treated with 50 mM of cisplatin
for 1 h and after 24 h the percentage of sub-G1 cells (as an
indicator of cell death) was determined by flow cytometry.
Reduced expression of hsa-miR-424 or hsa-miR-340 did not
significantly improve cisplatin cytotoxicity (data not shown),
whereas increased expression of hsa-miR-302b significantly
enhanced cisplatin cytotoxicity, with an increase of cell death
ranging from 26.5 to 43.9% in 6 independent experiments as
compared to negative scrambled-transfected cells (p,0.0001;
Fig. 3A). No significant differences in cell growth were observed
between IGROV-1 cells transiently transfected with hsa-miR-
302b precursor molecule and control cells (Fig. 3B), ruling out the
possibility that hsa-miR-302b sensitized cancer cells to cisplatin by
stimulating cell proliferation.
HDAC4 is Directly Targeted by hsa-miR-302b in IGROV-1
Cells
Because the effects of miRNAs might lead to expression changes
in their predicted target genes, we searched for expression patterns
deregulated following CpG-ODN treatment by integrating the
miRNA and mRNA expression profiles. Class comparison of
whole gene expression, previously identified by Illumina Hu-
manHT12_v3 beadchips using the same RNA samples assessed for
miRNA profile [3], revealed 215 genes differentially expressed
(141 up-regulated in saline- and 74 in CpG-ODN treated mice;
FDR,0.1 and fold change .1.8).
To identify functional miRNA-mRNA relationships, miRNA
and mRNA data were integrated using the freely available tool
MAGIA [19]. Given the frequent miRNA-miRNA interactions,
the 20 miRBase-annotated miRNAs were altogether compared to
the gene expression profile dataset using the union of Pita,
miRanda and TargetScan prediction target algorithms available
on MAGIA. The Pearson’s correlation between each miRNA and
its predicted target was then computed. The first 250 most
significantly negatively correlated miRNA-mRNA interactions
were visualized as a network using Cytoscope. Evidence of the
concerted interplay of miRNAs regulated by CpG-ODN and their
potential target mRNAs was observed (Fig. 4) for 2 miRNAs
upregulated (hsa-miR-302b and hsa-miR-374b) and for 13
miRNAs downregulated in CpG-ODN-treated mice (hsa-miR-
135a, hsa-miR-136, hsa-miR-340, hsa-miR-445-5p, hsa-miR-424,
hsa-miR-96, hsa-miR-142-3p, hsa-miR-140-5p, hsa-miR-542-3p,
hsa-miR-18a, hsa-miR-18b, hsa-miR-101, and hsa-miR-99a). The
latter 13 form a highly interconnected cluster where different
miRNAs exert their biological functions targeting the same genes.
Focusing on the 19 genes potentially targeted by hsa-miR-302b
as identified using MAGIA (q value ,0.1, Table S1), we evaluated
HDAC4, one of the top anti-correlated mRNAs, as a potential
molecular target of hsa-miR-302b associated with response to
chemotherapy. HDAC4, a member of the histone deacetylase
family, encodes a protein that reportedly mediates cisplatin
sensitivity in ovarian cancer [27]. Forced hsa-miR-302b expres-
sion in IGROV-1 cells decreased HDAC4 mRNA and protein
levels (Fig. 5A and B), supporting the interaction analysis data. To
determine whether the down-modulation of HDAC4 after hsa-
miR-302b overexpression was due to a direct interaction between
the miRNA and the mRNA of HDAC4, a luciferase reporter assay
was performed. Briefly, the target site of hsa-miR-302b was
identified within the HDAC4 39UTR according to the Target
Scan database (Fig. 5C), and the region including this site was
cloned downstream of the luciferase gene into the reporter plasmid
pGL3 control. Analysis of IGROV-1 cells co-transfected with hsa-
miR-302b precursor or a scrambled oligonucleotide and the
reporter vector, containing HDAC4 39UTR, revealed a significant
decrease in luciferase activity in hsa-miR-302b transfected cells as
compared to scrambled transfected cells (,50% reduction,
p = 0.0088, Fig. 5D), whereas mutated HDAC4-39UTR escaped
this inhibition (Fig. 5E). These data indicate the direct effect of
hsa-miR-302b on HDAC4 gene expression.
CpG-ODN-modulated miRNAs and Ovarian Cancer
Patients’ Clinical Course
The impact of expression levels of all 20 differentially expressed
miRNAs, including those for which validation was not carried out,
on the clinical course of ovarian cancer patients undergoing
chemotherapy was evaluated in silico. The time to relapse (TTR)
and overall survival (OS) with respect to each miRNA on two
public datasets (GSE25204 and GSE27290) [21;22] were
analyzed. Patients were stratified according to miRNA expression
below (low expression) or above (high expression) the median
expression value. In Bagnoli’s dataset [22], Kaplan-Meier analysis
showed that patients with low expression of hsa-miR-302b or with
high expression of hsa-miR-340 had a shorter TTR (log-rank,
P= 0.037; HR=1.75, 95% CI: 1.03–2.95 and P= 0.047;
HR=1.7, 95% CI: 1.01–2.86, respectively) (Fig. 6A and 6B).
Median TTR was 11 and 25 months for low and high expression
of hsa-miR-302b (Fig. 6A), and 26 and 12 months for low and high
expression of hsa-miR-340, respectively (Fig. 6B). In Shih’s dataset
[21], only the expression of hsa-miR-302b was significantly
associated to OS (log-rank, P = 0.034; HR=2.02, 95%CI: 1.05–
3.88), with a median OS of 33.7 and 101.2 months for low and
high expression, respectively (Fig. 6C). In both datasets, the impact
of the other 18 miRNAs expression was not significantly associated
to TTR or OS (data not shown).
Discussion
miRNAs are a ubiquitous feature of all cells, and functional
studies prompted by the growing number of miRNA targets
identified have demonstrated the involvement of miRNAs in the
regulation of almost every cellular process investigated, including
development, proliferation, differentiation, apoptosis, and tumor-
igenesis [28]. Moreover, emerging evidence suggests that miRNAs
play important roles in the regulation of immunological functions,
including innate immune responses of macrophages and the
development, differentiation, and function of T and B cells
[29;30].
Changes in miRNA expression induced by TLR ligand
stimulation have been broadly investigated for their impact on
development and function of innate immune cells, the primary
expressors of TLRs [31]. Here, we show that in vivo treatment with
TLR9 agonist CpG-ODNs also induces modulation of several
miRNAs in tumor cells. This modulation is unlikely to reflect a
direct action of CpG-ODN on IGROV-1 cells, which do not
express TLR9 and do not respond to murine CpG-ODN, and
instead is likely mediated by TLR9-positive cells in the tumor
microenvironment directly and/or through soluble factors. More-
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over, several studies indicating that miRNAs can also be
transferred between cells, e.g., through exosomes [32], as a
mechanism to interact and exchange information raises the
intriguing possibility that the immune system responds to CpG-
ODN treatment by boosting miRNA modulation and interaction
with tumor cells.
Our analysis of 3 miRNAs (hsa-miR-424, hsa-miR-340 and hsa-
miR-302b) for their relevance to chemotherapy response showed
that the enforced expression of hsa-miR-302b on IGROV-1 cells
significantly enhanced cisplatin cytotoxicity. Consistent with
in vitro data, hsa-miR-302b expression was significantly associated
to TTR or OS in two datasets of ovarian cancer patients treated
with platinum-based therapy. These findings indicate that hsa-
miR-302b acts as a ‘‘chemosensitizer’’ in human ovarian
carcinoma cells and may represent a biomarker able to predict
response to cisplatin treatment, leading to a more accurate
selection of patients potentially responsive to a specific therapy.
Moreover, the correlation between miRNA expression and
response to specific therapies also suggests the potential usefulness
of miRNAs as therapeutic adjuvants. Notably, whereas to date this
hypothesis mainly derives from in vitro gain- or loss-of-function
studies, where candidate miRNAs are identified in tumor cell lines
with different degrees of sensitivity to specific therapeutic drugs
and then targeted in order to overcome drug resistance, by
contrast our study starts using an in vivo model to select a candidate
miRNA, then validated in vitro as adjuvant tool and in human
samples as predictive biomarker.
The integration of miRNA and mRNA expression profiles upon
CpG-ODN treatment revealed a broad concerted interplay of
miRNAs with their predicted target mRNAs, suggesting a relevant
role for miRNAs in CpG-ODN-induced expression of genes
involved in different cellular pathways. Concerning genes involved
in DNA repair, miRNA-mRNA interaction analysis identified
HDAC4 as a gene potentially targeted by hsa-miR-302b, as then
validated by the decreased HDAC4 mRNA and protein levels
upon enforced hsa-miR-302b expression in IGROV-1 cells.
Inhibition of HDAC has been reported to induce hyperacetylation
of core histones and consequent relaxation of chromatin structure;
such an open chromatin configuration would be expected to
increase accessibility of genomic DNA to drugs targeting DNA
[33;34]. These data have led to clinical studies using HDAC
inhibitors in combination with current DNA damaging agents,
such as topoisomerase inhibitors, DNA synthesis inhibitors, DNA
intercalators and agents that covalently modify DNA, as treatment
of several types of cancer [34;35]. However, whereas clinical
studies have shown efficacy against human hematologic malig-
nancies, results in solid tumor trials have been unsatisfactory
because of some HDAC inhibitor limitations such as cardiac
toxicity [36;37]. The observation that overexpression of miR-302b
increased the sensitivity of ovarian tumor cells to cisplatin, together
with the reported tissue specificity of miRNAs [38], raises the
possibility of using this miRNA to modulate DNA-damaging drug
sensitivity and avoiding HDAC inhibitor toxicity. Moreover, a
very recent study reports direct regulation of p21 protein by
members of the miR-302 family activated following DNA damage
in human embryonic stem cells [20], further suggesting that miR-
302 can impact the response to DNA-damaging agents by
modulating different target molecules.
Overall, miRNA modulators are no longer merely theoretical,
as evidenced by the recent demonstration that inhibition of hsa-
miR-122 reduces viral load in hepatitis C patients [39], and
instead are strong candidates as therapeutic agents [39].
Supporting Information
Figure S1 qRT-PCR validation of CpG-ODN miRNA
profile. Comparison of hsa-miR-18a, hsa-miR-18b, hsa-miR-
140-5p, hsa-miR-101, hsa-miR-556-3p, hsa-miR-424, hsa-miR-
136, hsa-miR-340, hsa-miR-302b expression obtained by miRNA
expression profile and qRT-PCR on tumors collected from human
IGROV-1 ovarian tumor-bearing mice treated daily i.p. with
CpG-ODN or saline (control group). P values of differential
expression between control and CpG-ODN-treated IGROV-1
xenografts are reported. qRT-PCR data are plotted as -DCt and
array data are plotted as log2 (expression).
(TIF)
Table S1 MAGIA output representing 699 interactions
between miRNA and mRNA of CpG-ODN-treated tu-
mors with q value,0.1.
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methods.
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